508 filings
Page 3 of 26
8-K
dkfmuz3mt f7racgy4ed
23 May 22
Submission of Matters to a Vote of Security Holders
4:31pm
8-K
9kwy0q1fu8y09
28 Apr 22
Results of Operations and Financial Condition
8:10am
DEFA14A
ks1wd
5 Apr 22
Additional proxy soliciting materials
4:21pm
8-K
amx7 t9lp
5 Apr 22
Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors
4:16pm
8-K
xsxl x3wesgtkd7ar
4 Apr 22
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
7:35am
8-K
yqayk8x4bgh7g32rdetc
17 Mar 22
Other Events
7:36am
8-K
w8lfpq8y eccep
10 Feb 22
Results of Operations and Financial Condition
8:10am
8-K
qih9w15 0zlmdptj2kxz
10 Jan 22
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates
7:01am
8-K
6zej yrwlt
4 Jan 22
Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President
4:16pm
8-K
w5x5t8w5tz60onc1j
20 Dec 21
Departure of Directors or Certain Officers
4:15pm
8-K
fbkfgmlinkhdblq
28 Oct 21
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
8:11am
8-K
rpu3mhbyeatk0d9
8 Sep 21
Departure of Directors or Certain Officers
8:35am
8-K
l7juy3wp cs9j
3 Aug 21
Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights
8:10am
8-K
68drqr5qjvb tcrc1o
21 May 21
Submission of Matters to a Vote of Security Holders
4:30pm